246 related articles for article (PubMed ID: 22441895)
41. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
[TBL] [Abstract][Full Text] [Related]
42. The genetic basis of breast cancer and its clinical implications.
Bennett IC; Gattas M; Teh BT
Aust N Z J Surg; 1999 Feb; 69(2):95-105. PubMed ID: 10030809
[TBL] [Abstract][Full Text] [Related]
43. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
44. Heterozygous mutations in PALB2 cause DNA replication and damage response defects.
Nikkilä J; Parplys AC; Pylkäs K; Bose M; Huo Y; Borgmann K; Rapakko K; Nieminen P; Xia B; Pospiech H; Winqvist R
Nat Commun; 2013; 4():2578. PubMed ID: 24153426
[TBL] [Abstract][Full Text] [Related]
45. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
[TBL] [Abstract][Full Text] [Related]
46. BRCA in breast cancer: ESMO clinical recommendations.
Balmaña J; Díez O; Castiglione M;
Ann Oncol; 2009 May; 20 Suppl 4():19-20. PubMed ID: 19454451
[No Abstract] [Full Text] [Related]
47. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways.
Keimling M; Volcic M; Csernok A; Wieland B; Dörk T; Wiesmüller L
FASEB J; 2011 Nov; 25(11):3849-60. PubMed ID: 21778326
[TBL] [Abstract][Full Text] [Related]
48. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
49. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
[TBL] [Abstract][Full Text] [Related]
50. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
51. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
[TBL] [Abstract][Full Text] [Related]
52. Genetic variants associated with breast-cancer risk.
Narod SA
Lancet Oncol; 2011 May; 12(5):415-6. PubMed ID: 21514220
[No Abstract] [Full Text] [Related]
53. Heritable Gastrointestinal Cancer Syndromes.
Stoffel EM
Gastroenterol Clin North Am; 2016 Sep; 45(3):509-27. PubMed ID: 27546846
[TBL] [Abstract][Full Text] [Related]
54. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
55. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
56. Hereditary cancers in obstetrics and gynecology.
Swisher E
Clin Obstet Gynecol; 2001 Sep; 44(3):450-63. PubMed ID: 11685871
[TBL] [Abstract][Full Text] [Related]
57. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
58. Endocrine tumors associated with neurofibromatosis type 1, Peutz-Jeghers syndrome and other familial neoplasia syndromes.
Kalkan E; Waguespack SG
Front Horm Res; 2013; 41():166-81. PubMed ID: 23652677
[TBL] [Abstract][Full Text] [Related]
59. Genetic testing for cancer predisposition.
Eng C; Hampel H; de la Chapelle A
Annu Rev Med; 2001; 52():371-400. PubMed ID: 11160785
[TBL] [Abstract][Full Text] [Related]
60. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
